Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization.

Wenxin XuJialei WengMinghao XuQiang ZhouShaoqing LiuZhiqiu HuNing Ren Chenhao Zhou Ying-Hao Shen

Published in: Cancer immunology, immunotherapy : CII (2024)

CCL21 may serve as a predictive biomarker for immunotherapy response in HCC patients. High levels of CCL21 in TME inhibit immunosuppressive polarization of neutrophils. CCL21 in combination with ICIs may offer a novel therapeutic strategy for HCC.

Keyphrases

liver fibrosis
liver injury
end stage renal disease
drug induced
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes